FDA Approves Darzalex Faspro for Treating Multiple Myeloma
WEBAug 8, 2024 · By Lori Solomon HealthDay Reporter. WEDNESDAY, Aug. 7, 2024 -- The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (MM) who are eligible for ...
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEBDec 13, 2023 · By Elana Gotkine HealthDay Reporter. WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D …
Multiple Myeloma News & Updates - Drugs.com
WEBMay 8, 2024 · FDA Approves Carvykti for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy HORSHAM, PA (April 5, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) …
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
WEBApr 9, 2024 · The approval is for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is a one-time infusion, with a new recommended dose range …
FDA Approves Carvykti for Patients with Relapsed or Refractory …
WEBAbout Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 5 In multiple myeloma, these plasma cells change, spread rapidly and replace normal cells in the bone marrow with tumors. 6 In 2024, it is estimated that more than 35,000 people ...
Updated Linvoseltamab Data Showcase Continued Deepening of …
WEBAbout Multiple Myeloma As the second most common blood cancer, there are over 176,000 new cases of MM diagnosed globally, and 35,000 cases are diagnosed in the U.S. every year. In the U.S., there are approximately 8,000 people who have MM that has progressed after three lines of therapy, and 4,000 whose disease has progressed after four or more ...
Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based …
WEBAbout Multiple Myeloma Multiple myeloma is a blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 3 In multiple myeloma, these malignant plasma cells proliferate and replace normal cells in the bone marrow. 4 Multiple myeloma is the second most common blood cancer worldwide and remains an ...
Velcade (bortezomib): Uses, Dosage & Side Effects - Drugs.com
WEBMay 8, 2024 · Velcade (bortezomib) is used to treat multiple myeloma (MM) and mantle cell lymphoma (MCL) in adults. Velcade injection is a proteasome inhibitor, a type of targeted cancer drug. Velcade injection is not chemotherapy. Velcade works by blocking enzymes (proteasomes), which usually break down proteins inside cancer cells.
List of 59 Multiple Myeloma Medications Compared - Drugs.com
WEBMultiple myeloma is a type of cancer that forms in plasma cells (also called mature B-lymphocytes), which are a type of white blood cell that is made in the bone marrow. Multiple myeloma treatments aim to manage symptoms, slow disease progression, and improve quality of life. They typically involve a combination of therapies, such as:
Racial, Ethnic Differences ID'd for Idecabtagene Vicleucel in …
WEBBy Elana Gotkine HealthDay Reporter. WEDNESDAY, Oct. 25, 2023 -- There are some racial and ethnic differences in safety and response to standard of care (SOC) idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM), according to a study published online Oct. 16 in Blood Advances.